Informing materials: drugs as tools for exploring cancer mechanisms and pathways
- 18 May 2017
- journal article
- research article
- Published by Springer Nature in History and Philosophy of the Life Sciences
- Vol. 39 (2) , 1-23
Abstract
This paper builds on previous work that investigated anticancer drugs as ‘informed materials’, i.e., substances that undergo an informational enrichment that situates them in a dense relational web of qualifications and measurements generated by clinical experiments and clinical trials. The paper analyzes the recent transformation of anticancer drugs from ‘informed’ to ‘informing material’. Briefly put: in the post-genomic era, anti-cancer drugs have become instruments for the production of new biological, pathological, and therapeutic insights into the underlying etiology and evolution of cancer. Genomic platforms characterize individual patients’ tumors based on their mutational landscapes. As part of this new approach, drugs targeting specific mutations transcend informational enrichment to become tools for informing (and destabilizing) their targets, while also problematizing the very notion of a ‘target’. In other words, they have become tools for the exploration of cancer pathways and mechanisms. While several studies in the philosophy and history of biomedicine have called attention to the heuristic relevance and experimental use of drugs, few have investigated concrete instances of this role of drugs in clinical research.Keywords
Funding Information
- Société et culture (Postdoctoral Fellowship, FRQSC SE-164195)
- Canadian Institutes of Health Research (CIHR MOP-93553)
This publication has 71 references indexed in Scilit:
- Biomarkers, the molecular gaze and the transformation of cancer survivorshipBioSocieties, 2013
- Genome Sequencing Identifies a Basis for Everolimus SensitivityScience, 2012
- A theoretical framework for early human studies: uncertainty, intervention ensembles, and boundariesTrials, 2012
- Cancer cells and adaptive explanationsBiology & Philosophy, 2012
- The pharmaceuticalisation of society? A framework for analysisSociology of Health & Illness, 2011
- Ras in Cancer and Developmental DiseasesGenes & Cancer, 2011
- Desperately seeking cancer drugs: explaining the emergence and outcomes of accelerated pharmaceutical regulationSociology of Health & Illness, 2011
- Linking Molecules to Mood: New Insight Into the Biology of DepressionAmerican Journal of Psychiatry, 2010
- American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody TherapyJournal of Clinical Oncology, 2009
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal CancerNew England Journal of Medicine, 2008